person · Reporting owner
Tong Victor Edward Jr
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aardvark Therapeutics, Inc.AARD · Entity 6598 | Director | August 14, 2026 | August 21, 2026 |
| CG Oncology, Inc.CGON · Entity 3735 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aardvark Therapeutics, Inc.
Report date August 14, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.54 · Expires 2036-08-14 | Direct | 44,964 |
Reported balance
After 2026-08-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 44,964 · Balance 44,964 F1: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive.
CG Oncology, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.09 · Expires 2036-06-03 | Direct | 9,354 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 9,354 · Balance 9,354 F1: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 21, 2026 23:45 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | GrantStock Option (right to buy) · Derivative | 44,964 | $0.00 Strike: $6.54 | $0.00 |
DisclosureSEC source: 0001193125-26-361481 · ownership.xml · derivative · entry 1 Tong Victor Edward Jr · CIK 0002007923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,964 Underlying: Common Stock · 44,964 shares Expires 2036-08-14 F1 · derivative.exercise_date: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantDirector Stock Option (right to buy) · Derivative | 9,354 | $0.00 Strike: $56.09 | $0.00 |
DisclosureSEC source: 0001193125-26-259693 · ownership.xml · derivative · entry 1 Tong Victor Edward Jr · CIK 0002007923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,354 Underlying: Common Stock · 9,354 shares Expires 2036-06-03 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:05 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | GrantStock Option (right to buy) · Derivative | 61,017 | $0.00 Strike: $11.29 | $0.00 |
DisclosureSEC source: 0000950170-25-086140 · ownership.xml · derivative · entry 1 Tong Victor Edward Jr · CIK 0002007923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,017 Underlying: Common Stock · 61,017 shares Expires 2035-06-11 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option will vest on June 11, 2026, and 1/36th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 21:00 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantDirector Stock Option (right to buy) · Derivative | 24,165 | $0.00 Strike: $26.63 | $0.00 |
DisclosureSEC source: 0000950170-25-083236 · ownership.xml · derivative · entry 1 Tong Victor Edward Jr · CIK 0002007923 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,165 Underlying: Common Stock · 24,165 shares Expires 2035-06-04 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 5, 2025, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| October 04, 2024 Filed Oct 7, 2024 21:07 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantStock Option (Right to Buy) · Derivative | 15,600 | $0.00 Strike: $36.63 | $0.00 |
DisclosureSEC source: 0000950170-24-113310 · ownership.xml · derivative · entry 1 Tong Victor Edward Jr · CIK 0002007923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,600 Underlying: Common Stock · 15,600 shares Expires 2034-10-03 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following October 4, 2024, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.